Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07215611 · ClinicalTrials.gov registry record

Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

A clinical trial of Financial Toxicity and Bone Sarcomas, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT07215611 is a study of Financial Toxicity and Bone Sarcomas that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, above the 78-participant average among 5 other Financial Toxicity trials with a reported enrollment target (28% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07215611, a study of Financial Toxicity and Bone Sarcomas, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

To learn about the financial stress patients undergoing surgery to treat orthopedic cancer experience because of the costs of cancer care, and to learn about the effects of financial stress on participants quality of life.

Interventions

  • OTHER data collection

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-09-02
Est. Completion 2030-10-02

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT07215611

The ClinicalTrials.gov registry entry for NCT07215611 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 78-participant average among 5 other Financial Toxicity trials with a reported enrollment target (28% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Financial Toxicity appearing as the primary indexed condition, and to 1 intervention - of which data collection is the first listed.

NCT07215611 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07215611 about?

NCT07215611 is a clinical study titled "Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas". To learn about the financial stress patients undergoing surgery to treat orthopedic cancer experience because of the costs of cancer care, and to learn about the effects of financial stress on participants quality of life.

What is the current status of trial NCT07215611?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-09-02. Estimated completion is 2030-10-02.

What conditions does trial NCT07215611 study?

This clinical trial studies the following conditions: Financial Toxicity, Bone Sarcomas.

What interventions are being tested in trial NCT07215611?

The interventions under investigation include: data collection (OTHER).

Who is sponsoring clinical trial NCT07215611?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07215611 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Financial Toxicity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.